the phase II study of chemotherapy with Docetaxel+Nedaplatin+5-FU(DNF) to esophageal cancer - the phase II study of DNF therapy to esophageal cancer

Gunma University Graduate School Department of General Surgical Science0 个研究点目标入组 30 人开始时间: 2011年2月14日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•1.It is the patient having an anaphylactic history for DOC, CDGP, 5-FU and polysorbate "80" component pharmaceutical. 2.Severe complicate disease (malignant hypertension, severe heart failure, liver failure, liver cirrhosis, diabetes mellitus under inadequate control, bleeding disorders) 3.Infectious disease with fever up 4.Regardless of presence of a cause, it is motor paralysis, the patient having peripheral neuropathy, severe edema 5.pleural effusion or cardiac effusion need to treatment. 6.The patient having active multiple primary cancer. 7.During the pregnancy or a pregnant female patient we are possible or are nursing. 8.The patient having the interstitial pneumonia that is apparent by chest X-rays or CT or pulmonary fibrosis 9.The patient whom we merge psychosis or neurologic manifestation, and it is judged to have difficulty with participation to an examination. 10.the case that resarch contact doctor regards as inadequate

发起方

Gunma University Graduate School Department of General Surgical Science